We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Researchers have found that some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions about reimbursing cancer drugs following European Medicines Agency (EMA) approval.